Experts suggest that the increase in incidence of high blood pressure among children and adolescents is linked to the growing pediatric obesity epidemic.
John Orloff, senior vice president, medical and drug regulatory affairs, Novartis Pharmaceuticals, said: “Novartis believes it is important to provide physicians with treatment options such as Diovan which are effective in treating high blood pressure in this vulnerable population of children and adolescents.”